{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=23", "query": { "condition": "Metastatic Solid Tumor Cancers", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 1751, "total_pages": 176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T11:50:44.991Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06960395", "title": "Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor Malignancies", "EGFR Positive Solid Tumors", "EGFR" ], "interventions": [ { "name": "VIR-5525", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vir Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2025-07-22", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Houston, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06960395" }, { "nct_id": "NCT01358903", "title": "A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "RO5429083", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2011-06", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358903" }, { "nct_id": "NCT07454642", "title": "AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Vulvar Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Small Cell Carcinoma of Lung", "Colorectal Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "AVA6103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avacta Life Sciences Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2026-03-31", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07454642" }, { "nct_id": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Lymphoma, Non-Hodgkin", "Mantle Cell Lymphoma", "Bladder Cancer", "Uveal Melanoma, Recurrent", "Cervix Cancer", "Carcinoma in Situ", "Head and Neck Squamous Cell Carcinoma", "Skin Cancer", "Metastatic Cancer", "Tumor, Solid", "Tumor Recurrence" ], "interventions": [ { "name": "ONM-501", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoNano Medicine, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2023-10-13", "completion_date": "2026-08-29", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 9, "location_summary": "Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tamarac", "state": "Florida" }, { "city": "Canton", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06022029" }, { "nct_id": "NCT03030378", "title": "Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Edodekin alfa", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-05-30", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 27, "location_summary": "Sacramento, California • San Francisco, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030378" }, { "nct_id": "NCT00001397", "title": "Evaluation, Treatment, and Training for Patients With Blood Disorders", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "2 Years to 110 Years" }, "enrollment_count": 1452, "start_date": "1993-11-08", "completion_date": "2020-10-05", "has_results": false, "last_update_posted_date": "2020-10-08", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001397" }, { "nct_id": "NCT00276913", "title": "A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "STA-5312", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synta Pharmaceuticals Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00276913" }, { "nct_id": "NCT06056024", "title": "A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, KRAS Mutation" ], "interventions": [ { "name": "BI 3706674", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2023-12-06", "completion_date": "2025-12-17", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 6, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Boston, Massachusetts + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056024" }, { "nct_id": "NCT04068194", "title": "Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Unresectable Cholangiocarcinoma", "Locally Advanced Unresectable Gallbladder Carcinoma", "Locally Advanced Unresectable Malignant Solid Neoplasm", "Metastatic Cholangiocarcinoma", "Metastatic Gallbladder Carcinoma", "Metastatic Malignant Solid Neoplasm", "Stage III Gallbladder Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Peposertib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2020-04-07", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 46, "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 34 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068194" }, { "nct_id": "NCT06799065", "title": "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer Recurrent", "Ovarian Cancer", "High-grade Serous Ovarian Carcinoma", "Triple Negative Breast Cancer", "sqNSCLC", "Squamous Non-small-cell Lung Cancer" ], "interventions": [ { "name": "ATX-295", "type": "DRUG" }, { "name": "ATX-295 and bevacizumab (or biosimilar)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accent Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2025-03-21", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T11:50:44.991Z", "location_count": 11, "location_summary": "Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799065" } ] }